Skip to main content
Fig. 3 | Insights into Imaging

Fig. 3

From: Single-centre survival analysis over 10 years after MR-guided radiofrequency ablation of liver metastases from different tumour entities

Fig. 3

Kaplan–Meier curve depicts hepatic PFS of the whole study cohort in 73/109 patients (66.9%; a). Thereof, RFA treated lesions up to 29 mm, revealed longer hepatic PFS, compared to lesions over 30 mm (b however not statistically significant p = 0.092). Patients with NET and CRC revealed the highest hepatic PFS (c median 24.2 and 13.0 months, SD 3.9, 95% CI 5.2–20.9). Lowest hepatic PFS showed melanoma patients (c median 4.1 months, SD 2.1; 95% CI 0.1–8.2). Extrahepatic PFS of the whole study cohort occurred after median 37.0 months (d SD 9.3; 95% CI 18.7–55.2). Thereof highest extrahepatic PFS was documented for RFA-treated lesions up to 9 mm (e median 135.2 months, SD 96.2; 95% CI 0–323.9) and for patients with NET (f median 156.5 months)

Back to article page